Product development options

Based on the patent-protected technologies Tolerogenics S.à.r.l. has designed a pipeline of products for development.

The technologies can be employed to enhance existing immunotherapy approaches or to develop novel peptide-based approaches.

Tolerogenics S.à.r.l.is developing novel allergy immunotherapies against hymenoptera insect venom allergy, house dust mite allergy and birch tree pollen allergy.

Cooperations or partnerships for the development of other allergy or autoimmune disease immunotherapies are welcome.

Investors are invited to contact us for more information.